Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 27 of 65 · 3110 articles
This preclinical study suggests a heat‑killed form of Lactobacillus acidophilus LA‑5 reduced inflammation, oxidative stress, and markers of regulated cell death in a mouse model of ulcerative colitis — with effects...
Cure8 found this source from Journal of gastroenterology and hepatology, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Research and clinical trials. Open the original...
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...
FUT2-dependent intestinal fucosylation helps shape which gut microbes thrive and how the mucosa resists pathogens. For people with IBD, differences in FUT2 function and altered fucosylation may contribute to microbiome...
This study provides preclinical evidence that an anthocyanin (cyanidin-3-O-glucoside) can reduce inflammation and preserve the intestinal barrier in a mouse colitis model, highlighting a possible dietary mechanism...
If blood bile acid patterns are reproducibly different in IBD and track with disease activity, they could become noninvasive biomarkers to help diagnose IBD or monitor flares. That would be useful for patients and...
Macrophage behavior and metabolic reprogramming help drive inflammation or repair in ulcerative colitis, so understanding these processes could point to new therapies. The review links lab methods and ongoing clinical...
Psoriasis and Crohn’s disease share immune pathways that affect treatment choices. Some biologics work across both conditions while others (notably IL-17 inhibitors) may be inappropriate for patients with active IBD.
This study describes a novel colon-targeted microgel delivery system carrying an anti-inflammatory natural compound that, in a mouse model, reduced colitis signs and altered gut bacteria — a potential new strategy for...
This atlas maps when and where regenerative gene programs turn on in the intestine and highlights molecular features (like interferon responses and hypertranscription) that overlap with human Crohn’s disease, so it could...
Diet is a modifiable factor that could influence IBD risk through effects on the gut microbiome and immune pathways.
This registry study shows many people with IBD in Kazakhstan had clinically active disease at enrollment and identifies factors linked with active UC and CD. It highlights potential gaps in disease control and...
People with stricturing Crohn’s disease currently lack effective medical treatments to prevent or reverse intestinal fibrosis; this trial explores a probiotic approach (and trehalose) aimed at stimulating autophagy, a...
Drug developers use mass-balance (ADME) studies to learn how a new drug is absorbed and cleared, which helps guide dosing, safety testing, and further trials.
Long-term, real-world safety data help patients and clinicians understand risks — especially serious infections — when a newer ulcerative colitis drug is used in routine practice. This registry entry shows Pfizer is...
Researchers can use these human tissue slice cultures to study inflammation and test drugs on a patient’s own biopsy tissue, which could eventually help explain treatment response or resistance in IBD and related...
The study links a common dietary fiber (green banana resistant starch) to microbiota changes and production of propionate that protect the colonic barrier and reduce inflammation in a mouse model of ulcerative colitis.
This study proposes specific plant compounds and molecular pathways that could be relevant to ulcerative colitis, which may guide future lab research and drug-discovery efforts. For people with UC, it points to...
The study suggests molecular targets and pathways through which a traditional herbal formula might influence UC biology, offering testable hypotheses for future lab and clinical research.
Researchers are exploring ways to deliver drugs selectively to inflamed gut tissue in IBD to boost local effectiveness and reduce systemic side effects. Progress in smart nanoparticles and hydrogels could eventually...
Both EEN and the Crohn’s disease exclusion diet are used to induce remission in children with Crohn’s disease. Evidence that they perform similarly through 52 weeks may help families and clinicians choose the approach...
Knowing which symptoms and non-invasive biomarkers most strongly associate with UC can help patients and clinicians decide who should be prioritized for diagnostic endoscopy and for monitoring disease activity.
This study builds a large, public single-cell map of the gut in Crohn’s disease that identifies cell types and gene programs linked to inflammation. That can help researchers find new drug targets and explain why some...
IBD patients sometimes use dietary strategies and supplements like curcumin for inflammation. This study describes a food-processing method that preserves curcumin activity and targets release to the intestine in lab...
People with IBD may experience cognitive symptoms; this preclinical study identifies specific quercetin glycosides that protected mice from colitis-related cognitive decline via gut microbiota and tryptophan metabolism...
Researchers identified a plant-derived molecule (oxypalmatine) that reduced inflammation in a mouse colitis model by blocking pro-inflammatory macrophage activity through the RAB8A–STAT1 pathway. This suggests a...
The study suggests that timing of eating (time-restricted feeding) may influence intestinal inflammation and gut microbiota in ways that could be relevant to IBD. If confirmed in humans, meal timing could be a low-cost...
A plant polysaccharide (PVP) reduced inflammation and preserved intestinal barrier proteins in a mouse model of ulcerative colitis, apparently by increasing a specific gut bacterium. This points to a microbiome-related...
A new IL-17A drug (vunakizumab) is reported to have triggered severe ulcerative colitis in one patient, suggesting clinicians and patients starting IL-17A inhibitors should watch for early gastrointestinal symptoms.
Researchers are working to link specific gut microbes and their metabolites to host molecular changes in ulcerative colitis. This study maps candidate microbe–metabolite–host gene connections that could point to new...
This real-world multicenter study provides short-term effectiveness and safety data for upadacitinib in a difficult-to-treat Crohn’s population in China, which may inform treatment decisions and risk discussions.
These methods could help researchers and clinicians better identify which treatments are likely to work for which patients by combining trials and EHR data, accounting for multiple outcomes and missing data — relevant to...
If you have Crohn’s disease, upper GI biopsies showing focally enhanced gastritis or focally active inflammation could support a diagnosis of upper GI involvement and are associated with other histologic findings like...
People with IBD already have a higher baseline risk of colorectal cancer. This study finds that having multiple first‑degree relatives with CRC adds the largest absolute additional risk, which could affect how...
The study identifies Piezo1 in intestinal epithelial cells as a potential driver of intestinal fibrosis in IBD via a stiffness → ROS → partial EMT pathway, and suggests targeting Piezo1 or ROS could reduce fibrosis in...
If confirmed, molecular or microbial markers found at surgery could help identify Crohn’s patients at higher risk of postoperative endoscopic recurrence and inform closer monitoring or preventative strategies after...
Non-invasive, portable tests that can track inflammation more frequently could help patients and clinicians monitor disease activity between clinic visits and guide treatment decisions without repeated invasive...
The study identifies osteopontin as a stromal-secreted protein elevated in IBD-derived colonic fibroblasts and shows it can restrain epithelial maturation in human colonic organoids, a mechanistic insight that could be...
The findings suggest that early biologic and immunomodulator treatment may reduce the need for first surgery in Crohn's disease, which is directly relevant to treatment planning and expectations for people with IBD.
Switching biologics is a frequent and consequential decision in children with IBD; using TDM and a mechanism‑based approach can help choose whether to optimize, switch within class, or change drug class.
If you or a child had Kawasaki disease, this study suggests there may be a higher long-term chance of certain skin autoimmune conditions (psoriasis, vitiligo) but no clear increase in IBD or several other autoimmune...
Malnutrition was common and much more frequent during active Crohn’s disease in this South Asian cohort, which matters because poor nutritional status affects treatment tolerance, recovery, and quality of life.
Mental health conditions (depression, anxiety, ADHD) appear to increase before and after IBD diagnosis, suggesting psychological care may be needed earlier in the diagnostic pathway and long term.
The study highlights a bacterial gene that helps adherent-invasive E. coli (AIEC) colonize the gut — a mechanism that has been linked to Crohn's disease. Understanding how AIEC colonizes could guide future research into...
People with IBD are at higher risk for colorectal cancer; identifying stromal genes that track inflammation-driven EMT could help researchers find biomarkers or targets that explain how chronic inflammation promotes...
A blood test (serum REG3α) may help identify people at higher risk of developing complicated Crohn's disease years before diagnosis and predict progression in established disease, which could inform monitoring or early...
Physical activity may be a modifiable factor that could improve fitness, inflammation, symptoms like fatigue, and quality of life in children with IBD. This trial will provide objective, randomized data relevant to...
CAR-Treg and Treg-cell therapies aim to specifically suppress harmful gut inflammation and could offer a new treatment option for people whose IBD does not respond to current drugs. Right now this is early-stage work —...
